Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tadalafil
Drug ID BADD_D02106
Description Tadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy.[L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. In contrast to other PDE5 inhibitors like [sildenafil], tadalafil has greater selectivity for PDE5 and a longer half-life which has made it a more suitable option for chronic once-daily dosing in the treatment of PAH.[A242287]
Indications and Usage Used for the treatment of erectile dysfunction.
Marketing Status Prescription
ATC Code G04BE08
DrugBank ID DB00820
KEGG ID D02008
MeSH ID D000068581
PubChem ID 110635
TTD Drug ID D05MQK
NDC Product Code 69238-1348; 16729-370; 42291-787; 68981-043; 62512-0063; 68071-5186; 71205-400; 65862-850; 31722-644; 53747-050; 50268-739; 68071-2613; 71821-008; 72303-0825; 72761-017; 68071-5092; 42291-865; 76420-126; 71610-581; 31722-643; 68071-2553; 69238-1346; 70518-2450; 0002-4463; 27241-113; 60219-1349; 70771-1476; 51293-840; 33342-267; 13668-566; 43598-578; 65862-853; 13668-568; 68071-2451; 63629-8288; 71610-213; 0093-3016; 47335-009; 63629-7943; 0093-3017; 71610-603; 33342-266; 69238-1347; 73377-080; 0110-4464; 66302-467; 0110-4467; 13668-581; 13668-567; 70771-1477; 0093-3019; 67184-0524; 68462-779; 27241-114; 66039-921; 79572-033; 0002-4462; 16729-372; 42291-789; 68180-921; 69238-1349; 75834-249; 68071-4912; 42291-864; 71205-418; 50090-4247; 71335-1255; 47335-011; 62128-0385; 71335-1239; 29300-288; 68180-922; 33342-268; 71821-007; 29300-287; 42291-866; 35573-412; 69037-0015; 69097-374; 65372-1173; 71610-214; 69097-376; 43598-575; 45865-991; 68071-2632; 68462-782; 50090-5724; 47335-012; 0395-8085; 72303-0822; 71052-059; 68382-899; 50268-738; 33342-278; 38779-3062; 65862-851; 50436-0370; 68071-2554; 71335-1670; 62332-178; 69097-375; 43063-236; 16714-077; 60219-1346; 71610-298; 16714-074; 0110-4462; 46144-327; 68071-5116; 68462-781; 27241-123; 65862-852; 63275-9895; 43598-576; 0002-4464; 70518-2862; 69097-526; 68382-898; 62512-0056; 60219-1347; 66174-0021; 71205-268; 31722-645; 46708-177; 27241-112; 62756-028; 31722-646; 71335-1620; 51552-1550; 62332-180; 71610-353; 61919-887; 35573-409; 68071-2421; 50090-4753; 71205-502; 72303-0823; 65862-719; 50090-5344; 71335-1587; 42291-788; 71205-269; 63629-8409; 68462-780; 71610-325; 69097-373; 71610-354; 68180-920; 50090-5627; 47335-010; 60219-1348; 70518-3001; 61919-889; 67835-5045; 68071-5110; 13668-565; 75834-248; 71335-1823; 42291-786; 42291-804; 35573-411; 42291-867; 71610-461; 43353-044; 50090-4660; 67184-0525; 75834-247; 50090-5641; 49452-7596; 71821-009; 68180-919; 29300-286; 35573-410; 71335-1400; 0093-3018; 71610-303; 68071-5272; 46708-841; 70771-1475; 67184-0526; 50379-0005; 68071-5138; 81999-0006; 27241-111; 68180-914; 66039-843; 50090-4276; 51293-842; 46708-178; 43063-969; 68071-5182; 62991-3128; 43353-070; 71610-567; 16729-369; 63415-0117; 67184-0523; 72189-145; 16729-371; 16714-075; 16714-076; 31722-647; 75834-250; 64552-4047; 65862-880; 0110-4463; 43598-573; 68788-8153; 50090-5187; 72789-184; 33342-265; 0002-4465; 70771-1478; 70518-2972; 71335-1884; 43353-857; 90027-004; 46708-179; 62332-179; 63629-8157; 51293-839; 68071-5202; 0093-3334; 46708-180; 43598-574; 71335-1491; 68382-897; 29300-289; 51293-841; 68071-2417; 62332-177; 68382-896; 0110-4465; 63629-4601; 71821-006; 60592-742; 51927-5037; 72303-0824; 71610-324
Synonyms Tadalafil | Pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione, 6-(1,3- benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6R,12aR)- | IC351 | IC-351 | IC 351 | Cialis
Chemical Information
Molecular Formula C22H19N3O4
CAS Registry Number 171596-29-5
SMILES CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Respiratory arrest22.02.01.009--Not Available
Respiratory disorder22.02.07.0020.001439%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.002002%
Retinal artery occlusion24.01.07.003; 06.10.01.005--Not Available
Retinal detachment12.01.04.004; 06.09.03.0030.003837%
Retinal vascular occlusion24.04.10.004; 06.10.01.008--Not Available
Retinal vein occlusion24.01.07.006; 06.10.01.010--Not Available
Rhinitis22.07.03.006; 11.01.13.004--
Rhinorrhoea22.02.05.0100.001439%
Rib fracture15.08.07.001; 12.04.07.0010.000959%Not Available
Right ventricular failure02.05.03.0020.000375%Not Available
Scleroderma23.03.02.005; 15.06.01.002; 10.04.07.0010.000250%Not Available
Seizure17.12.03.001--
Sepsis11.01.11.003--
Septic shock24.06.02.011; 11.01.11.004--Not Available
Sexual dysfunction19.08.05.002; 21.03.02.0030.000959%Not Available
Shock24.06.02.002--Not Available
Sickle cell anaemia with crisis01.04.02.0010.000959%Not Available
Sinus bradycardia02.03.03.009--
Sinus congestion22.04.06.0010.001439%Not Available
Sinusitis22.07.03.007; 11.01.13.005--
Skin discolouration23.03.03.0050.001918%Not Available
Skin disorder23.03.03.007--Not Available
Sleep disorder19.02.04.001--Not Available
Somnolence17.02.04.006; 19.02.05.003--
Speech disorder22.02.05.034; 19.19.02.002; 17.02.08.003--Not Available
Splenic infarction24.04.07.003; 01.09.02.0040.001918%Not Available
Sputum discoloured22.02.03.0100.001918%Not Available
Squamous cell carcinoma16.16.01.0020.001439%Not Available
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 11.07.01.005; 10.01.03.020--
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 13 Pages